Argon Medical Devices Announces Exclusive License and Distribution Agreement for Optionâ„¢ Retrievable Inferior Vena Cava Filter
ATHENS, Texas, March 15, 2011 /PRNewswire/ -- Argon Medical Devices, Inc.  announced today that it has entered into a definitive license agreement with Rex Medical, LP ("Rex Medical") for exclusive global rights to market and distribute the Option™ Retrievable Inferior Vena Cava Filter, an implantable device used in the prevention of Pulmonary Embolism (PE).
"We are very pleased with the addition of Option™ to our product portfolio. This proven technology has rapidly become a leader in this disease segment due both to its efficacy and safety, and we are confident it will prove to be the preferred device of its kind," said George A. Leondis, President of Argon Medical Devices, Inc. "This partnership provides a compelling strategic opportunity for Argon, allowing us to provide our customers with another best in class product in the Interventional arena."
"Rex Medical is looking forward to again collaborating with Argon, on this innovative and pivotal technology," commented Lindsay L. Carter, President of Rex Medical, LP. "Argon's focused commitment to its customer base, coupled with its global sales and marketing presence and corresponding operational capabilities, make it the ideal partner."
Argon will be exhibiting at the 36th Annual Society of Interventional Radiology (SIR) Scientific Meeting, to be held in Chicago, IL from March 27-30, 2011.
About the Option™ Inferior Vena Cava Filter
The nitinol, Option™ IVC Filter, with a low profile 5Fr (6.5Fr O.D.) delivery system, is designed to be implanted into the inferior vena cava of patients to prevent recurrent PE. The filter is designed with symmetric flared struts to direct clot volume into the center of the vessel for maximum dissolution and preservation of blood flow allowing for capture of clinically significant clot and protection against PE. Designed as both a permanent or retrievable implant, thi